Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2683392 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL11099691 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1368985 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL12235723 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL15909556 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL12824048 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL584549 | 1.00 | NR1H2 (0.49) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL6421616 | 0.90 | NR1H2 (0.48) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL1722772 | 0.87 | CYP1A2 (0.45) | NR1H2CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20371652 | 0.87 | CYP1A2 (0.45) | NR1H2CYP1A2POLBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805311-B | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-114805311-A | Spirocyclic indenes | 苏州亚盛药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20160207949-A1 | NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| US-4424312-A | COPOLYMERIZING N-ACRYLOYL-4-(DIPHENYLPHOSPHINO)-2--(DIPHENYLPHOSPHINOMETHYL)PYRROLIDINE, RHODIUM COMPLEX | POLYMER SCIENCES CORPORATION (US) | 1984-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | NR1H2 2538/4885CYP1A2 2573/4885POLB 4473/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | NR1H2 2669/4885CYP1A2 2606/4885POLB 4449/4885 |
| US-20160207949-A1 | NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE | PDCD5, CD4, PDCD6 | NR1H2 2928/4885CYP1A2 3074/4885POLB 2576/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | NR1H2 1539/4885CYP1A2 4667/4885POLB 1699/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | NR1H2 2668/4885CYP1A2 2492/4885POLB 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.